Pharmaceutical Executive-02-01-2020

How current barriers along the roadway between biomarker testing and drug prescribing can affect decision-making for precision medicines.

Amid the growth but still-cautious embrace of social media and other digital marketing channels, appealing to the younger physician requires a nuanced approach-mixing proven expertise with fresh ideas.

Veteran pharma leader Jay Galeota shares learnings and perspectives from an off-the-beaten-path career rise-one driven today by a mission to align the industry’s risk-taking approach across the entire drug life cycle.

Exploring the advent of data analytics and pharma marketing automation in guiding targeted messaging and brand engagement.

With the nomination period for our latest Emerging Pharma Leaders selections in full swing, it's a good reminder that the industry's future path ultimately depends on its leaders, emerging and otherwise.

New OECD study doesn’t shed much light on the effectiveness of managed entry agreements for drug access.

Weighing new strategies to accelerate biomedical product development.

One ‘team’ model’s advantages in brand outreach and awareness.

Continued investment will mean new cures in a new decade.

Click the title above to open the Pharmaceutical Executive February 2020 issue in an interactive PDF format.

Eight lessons to drive better outsourcing decisions.

Hungary is fast staking a reputation for itself as one of Central and Eastern Europe’s most dynamic economies. A major factor has been pharmaceuticals, where Hungary’s history of research and production is reflected today in an attractive pharma investment landscape and the presence of home-grown success stories.